Deutsche Bank AG Buys 6,933 Shares of Disc Medicine, Inc. (NASDAQ:IRON)

Deutsche Bank AG lifted its position in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 75.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,093 shares of the company's stock after purchasing an additional 6,933 shares during the period. Deutsche Bank AG owned about 0.05% of Disc Medicine worth $1,020,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. Barclays PLC lifted its position in shares of Disc Medicine by 123.7% during the third quarter. Barclays PLC now owns 40,145 shares of the company's stock worth $1,972,000 after purchasing an additional 22,202 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Disc Medicine by 16.1% in the third quarter. JPMorgan Chase & Co. now owns 16,255 shares of the company's stock valued at $799,000 after acquiring an additional 2,257 shares in the last quarter. SG Americas Securities LLC raised its holdings in Disc Medicine by 66.0% in the fourth quarter. SG Americas Securities LLC now owns 8,076 shares of the company's stock valued at $512,000 after acquiring an additional 3,212 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Disc Medicine by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company's stock valued at $400,000 after acquiring an additional 593 shares in the last quarter. Finally, Bleakley Financial Group LLC acquired a new stake in Disc Medicine in the fourth quarter valued at approximately $486,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Disc Medicine news, insider William Jacob Savage sold 6,677 shares of the company's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $50.04, for a total value of $334,117.08. Following the transaction, the insider now directly owns 59,721 shares of the company's stock, valued at $2,988,438.84. This represents a 10.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Mona Ashiya sold 10,011 shares of the company's stock in a transaction that occurred on Friday, March 21st. The shares were sold at an average price of $54.00, for a total value of $540,594.00. Following the sale, the director now directly owns 187,297 shares in the company, valued at approximately $10,114,038. This represents a 5.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 349,510 shares of company stock valued at $18,936,535. Corporate insiders own 4.24% of the company's stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Cantor Fitzgerald raised their target price on shares of Disc Medicine from $99.00 to $132.00 and gave the company an "overweight" rating in a report on Tuesday, March 18th. TD Cowen assumed coverage on shares of Disc Medicine in a research report on Thursday, February 27th. They set a "buy" rating on the stock. BMO Capital Markets raised their target price on shares of Disc Medicine from $112.00 to $120.00 and gave the stock an "outperform" rating in a research report on Monday, May 12th. Scotiabank raised their target price on shares of Disc Medicine from $73.00 to $75.00 and gave the stock a "sector outperform" rating in a research report on Monday, March 3rd. Finally, Morgan Stanley reiterated an "overweight" rating and issued a $85.00 price objective on shares of Disc Medicine in a research report on Friday, March 7th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $98.80.

Disc Medicine Stock Performance

Disc Medicine stock traded down $0.11 during midday trading on Friday, reaching $46.76. The company's stock had a trading volume of 437,325 shares, compared to its average volume of 346,748. Disc Medicine, Inc. has a fifty-two week low of $30.82 and a fifty-two week high of $68.73. The stock's 50 day simple moving average is $45.07 and its 200 day simple moving average is $54.08. The firm has a market capitalization of $1.62 billion, a PE ratio of -11.75 and a beta of 0.77.

Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.03). Equities analysts predict that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.